Market Closed - Euronext Paris 12:35:29 2024-03-28 pm EDT 5-day change 1st Jan Change
5.7 EUR -1.21% Intraday chart for Nanobiotix -1.21% -14.16%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nanobiotix Gets $20 Million Milestone Payment in Phase 3 Trial for Potential Head, Neck Cancer Drug MT
Nanobiotix: targets achieved for NANORAY-312 CF
Nanobiotix Gets $20 Million Milestone Payment from Janssen MT
Nanobiotix: transfer of NBTXR3 rights in Asia CF
Nanobiotix Partner Transfers Asian Commercialization Rights for Oncology Therapy to Johnson & Johnson Unit MT
LianBio Assigns Rights to Nanobiotix's Oncology Therapy in China, Other Asian Markets to Janssen Pharmaceutica MT
ADRs Advance, Argo Blockchain PLC Climbs 35.0% DJ
Valneva Shareholders OK One-tier Governance Model; New Chair Appointed MT
Nanobiotix: closing of remaining JJDC placement CF
Nanobiotix Closes Issuance of Additional Shares to Johnson & Johnson Innovation – JJDC MT
Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc. CI
Johnson & Johnson Discloses Stake in Nanobiotix MT
Transcript : Nanobiotix S.A., Q3 2023 Earnings Call, Nov 14, 2023
Nanobiotix Raises EUR50.9 Million via Global Follow-on Offering MT
But where have the bears gone? Our Logo
ADRs Advance; Trivago N.V. Climbs 86.6% DJ
Nanobiotix Prices $55 Million Share Sale in US, Europe; Paris Stock Closes Lower MT
The Fed doesn't want to raise rates (but is pretending to) Our Logo
Nanobiotix Seeks $30 Million from Global Share Sale MT
Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc. CI
Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023 CI
Nanobiotix Says Pancreatic, Head, Neck Cancers Phase 1 Studies of NBTXR3 Show Higher Median Overall Survival MT
ADRs Advance, Akso Health Group Rises 29.6% DJ
Top Premarket Decliners MT
Transcript : Nanobiotix S.A. - Special Call
Chart Nanobiotix
More charts
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: NBTXR3, which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.7 EUR
Average target price
11.3 EUR
Spread / Average Target
+98.25%
Consensus
  1. Stock
  2. Equities
  3. Stock Nanobiotix - Euronext Paris
  4. News Nanobiotix
  5. Nanobiotix : Cancer Combo Therapy Shrinks Tumor in Early-Stage Study